[go: up one dir, main page]

WO2012108689A3 - 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도 - Google Patents

피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도 Download PDF

Info

Publication number
WO2012108689A3
WO2012108689A3 PCT/KR2012/000935 KR2012000935W WO2012108689A3 WO 2012108689 A3 WO2012108689 A3 WO 2012108689A3 KR 2012000935 W KR2012000935 W KR 2012000935W WO 2012108689 A3 WO2012108689 A3 WO 2012108689A3
Authority
WO
WIPO (PCT)
Prior art keywords
skin
whitening
oxidizing
activity
medical use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/000935
Other languages
English (en)
French (fr)
Other versions
WO2012108689A2 (ko
Inventor
정해영
박민희
하영미
한유경
박지영
박윤정
김진아
이지연
송유민
문형룡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Industry Cooperation Foundation of Pusan National University
Original Assignee
University Industry Cooperation Foundation of Pusan National University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Industry Cooperation Foundation of Pusan National University filed Critical University Industry Cooperation Foundation of Pusan National University
Priority to US13/984,567 priority Critical patent/US8889881B2/en
Priority to JP2013553357A priority patent/JP5856186B2/ja
Publication of WO2012108689A2 publication Critical patent/WO2012108689A2/ko
Publication of WO2012108689A3 publication Critical patent/WO2012108689A3/ko
Anticipated expiration legal-status Critical
Priority to US14/504,445 priority patent/US9155690B2/en
Priority to US14/838,381 priority patent/US10045923B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

본 발명은 피부미백, 항산화 및 PPAR 활성을 갖는 신규 화합물 및 이의 의학적 용도에 관한 것으로, 본 발명에 따른 화합물들은 티로시나아제를 억제하는 피부미백 활성을 지니므로 피부미백용 약학조성물 또는 화장품에 유용하게 사용될 수 있고, 항산화 활성을 지니므로 피부노화 등의 예방 또는 치료에 유용하게 사용될 수 있으며, 또한 PPAR 활성 특히, PPARα 및 PPARγ 활성을 지니므로 비만, 대사성 질환 또는 심혈관계 질환을 예방하고 치료하는 데에 유용한 약학조성물 또는 건강식품으로 사용될 수 있다.
PCT/KR2012/000935 2011-02-09 2012-02-08 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도 Ceased WO2012108689A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US13/984,567 US8889881B2 (en) 2011-02-09 2012-02-08 Compound having skin-whitening, anti-oxidizing and PPAR activities and medical use therefor
JP2013553357A JP5856186B2 (ja) 2011-02-09 2012-02-08 皮膚美白、抗酸化及びｐｐａｒ活性を有する新規化合物及びその医学的用途
US14/504,445 US9155690B2 (en) 2011-02-09 2014-10-02 Compound having skin-whitening, anti-oxidizing and PPAR activities and medical use thereof
US14/838,381 US10045923B2 (en) 2011-02-09 2015-08-28 Compound having skin-whitening, anti-oxidizing and PPAR activities and medical use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110011544A KR101395146B1 (ko) 2011-02-09 2011-02-09 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도
KR10-2011-0011544 2011-02-09

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/984,567 A-371-Of-International US8889881B2 (en) 2011-02-09 2012-02-08 Compound having skin-whitening, anti-oxidizing and PPAR activities and medical use therefor
US14/504,445 Continuation US9155690B2 (en) 2011-02-09 2014-10-02 Compound having skin-whitening, anti-oxidizing and PPAR activities and medical use thereof

Publications (2)

Publication Number Publication Date
WO2012108689A2 WO2012108689A2 (ko) 2012-08-16
WO2012108689A3 true WO2012108689A3 (ko) 2012-11-01

Family

ID=46639061

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/000935 Ceased WO2012108689A2 (ko) 2011-02-09 2012-02-08 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도

Country Status (4)

Country Link
US (3) US8889881B2 (ko)
JP (2) JP5856186B2 (ko)
KR (1) KR101395146B1 (ko)
WO (1) WO2012108689A2 (ko)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITVR20120003A1 (it) * 2012-01-05 2013-07-06 Univ Ferrara Nuove molecole dualistiche provviste di capacità filtrante uv ad ampio spettro e potente attività smorzatrice della reattività dei radicali liberi (radical scavenging)
GB201302927D0 (en) 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
EA030611B1 (ru) 2013-03-15 2018-08-31 Кэнсер Рисерч Текнолоджи, Ллк Способы и композиции для модуляции гамма-глутамилового цикла
US10452706B2 (en) * 2013-06-04 2019-10-22 Oath Inc. Method and system for handling images on a multi-touch device
KR101590546B1 (ko) * 2013-08-05 2016-02-01 건국대학교 산학협력단 1-메틸-1h-벤즈이미다졸 유도체를 유효성분으로 함유하는 항산화용 조성물
WO2015187082A1 (en) * 2014-06-02 2015-12-10 Lipigon Pharmaceuticals Ab New plasma lipid lowering agents
EP3189041B1 (en) 2014-09-03 2021-04-28 Ctxt Pty Ltd Tetrahydroisoquinoline derived prmt5-inhibitors
EP3189048B1 (en) 2014-09-03 2021-03-17 Ctxt Pty Ltd Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
CN104389045B (zh) * 2014-11-04 2016-05-18 黑龙江聚翔科技开发有限公司 一种热致液晶聚芳酯纤维的制备方法
GB201604030D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604031D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604029D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604020D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604022D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604027D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
US11844846B2 (en) 2018-05-16 2023-12-19 Emory University Styrylbenzothiazole derivatives and uses in imaging methods
CA3103623A1 (en) 2018-06-15 2019-12-19 Afecta Pharmaceuticals, Inc. Ccl5 inhibitors
KR102111048B1 (ko) * 2018-07-24 2020-05-14 부산대학교 산학협력단 신규한 디플루오로아세트산 유도체 화합물 및 이를 포함한 조성물
CN109456274B (zh) * 2018-12-07 2021-11-05 广东药科大学 苯并咪唑类衍生物、其制备方法及其作为药物的用途
HRP20250780T1 (hr) * 2019-01-31 2025-09-12 Spinogenix, Inc. Čvrsti oblici promotora spinogeneze
KR102777432B1 (ko) * 2019-02-19 2025-03-07 (주)애거슨바이오 모노메틸 푸마레이트 유도체 및 이들의 약학적 조성물
JP2023538326A (ja) * 2020-08-11 2023-09-07 ボード オブ トラスティーズ オブ ミシガン ステイト ユニバーシティ プロテアソームエンハンサ及びその使用
CN117209445A (zh) * 2023-09-12 2023-12-12 广州番禺职业技术学院 噻唑烷酚类衍生物及其制备方法与应用及美白霜

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846988A (en) * 1996-03-25 1998-12-08 Alcon Laboratories, Inc. Thiazolidine-4-carboxylic acid derivatives as cytoprotective agents
WO2004063155A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Fused heterocyclic derivatives as ppar modulators
US20050043398A1 (en) * 2003-08-18 2005-02-24 Christophe Carola Use of chromen-4-one derivatives
WO2006020916A2 (en) * 2004-08-13 2006-02-23 Metabolex, Inc. Modulators of ppar and methods of their preparation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754245A (fr) * 1969-08-01 1970-12-31 Sumitomo Chemical Co Derives d'acides phenoxy carboxyliques
US4020165A (en) * 1975-08-20 1977-04-26 Uniroyal Inc. Control of acarids using certain benzothiazoles or benzothiazolines
JPS54148783A (en) * 1978-04-25 1979-11-21 Santen Pharmaceutical Co Ltd Thiazolidine derivative
DE3172383D1 (en) * 1980-12-12 1985-10-24 Fine Organics Ltd Preparation of thiazolidine derivatives
US6068834A (en) * 1994-03-04 2000-05-30 The Procter & Gamble Company Skin lightening compositions
JP2002012535A (ja) * 2000-06-27 2002-01-15 Lion Corp メラニン脱色用組成物
FR2818128B1 (fr) * 2000-12-18 2004-04-02 Oreal Compositions cosmetiques antisolaires a base d'un melange synergetique de filtres et utilisations
US6861533B2 (en) * 2001-11-23 2005-03-01 Irm Llc Solution phase sythesis of arylbenzoxazoles
US7078421B2 (en) * 2002-03-20 2006-07-18 Metabolex, Inc. Substituted phenylacetic acids
US7524485B2 (en) * 2002-12-12 2009-04-28 Unilever Home & Personal Care, Usa, Division Of Conopco, Inc. Skin lightening agents, compositions and methods
EP1723127A4 (en) * 2004-02-11 2009-10-28 Univ Ohio State Res Found CELL PROLIFERATION INHIBITOR ANALOGS, METHODS OF MAKING SAME, AND USES THEREOF
FR2869615B1 (fr) * 2004-05-03 2007-11-16 Merck Sante Soc Par Actions Si Derives de l'acide butanoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et leurs applications therapeutiques
CN1939912A (zh) * 2005-10-01 2007-04-04 代斌 N－[2－(3－苯基－2－丙烯酰氨基)丙酰基]－噻唑烷酸及其衍生物制备方法
KR100729739B1 (ko) * 2006-01-06 2007-06-20 삼성전자주식회사 금속 화합물 및 이를 포함하는 유기 전계 발광 소자
US20080255213A1 (en) * 2007-04-14 2008-10-16 University Of Tennessee Research Foundation Thiazolidinone amides, thiazolidine carboxylic acid amides, and serine amides, including polyamine conjugates thereof, as selective anti-cancer agents
CN101407502B (zh) * 2008-11-21 2010-12-22 南京大学 一类n-(叔丁氧基羰基)噻唑烷酸类化合物及其制法和用途
KR101916489B1 (ko) * 2011-01-07 2018-11-07 알러간, 인코포레이티드 멜라닌 변형 조성물들 및 이의 사용 방법들
JP2014529628A (ja) * 2011-09-01 2014-11-13 ザ ジェネラル ホスピタル コーポレイション 皮膚色素沈着を調節するための方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846988A (en) * 1996-03-25 1998-12-08 Alcon Laboratories, Inc. Thiazolidine-4-carboxylic acid derivatives as cytoprotective agents
WO2004063155A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Fused heterocyclic derivatives as ppar modulators
US20050043398A1 (en) * 2003-08-18 2005-02-24 Christophe Carola Use of chromen-4-one derivatives
WO2006020916A2 (en) * 2004-08-13 2006-02-23 Metabolex, Inc. Modulators of ppar and methods of their preparation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE PUBCHEMCOMPOUND retrieved from http://pubchem.ncbi.nlm.nih.gov/search/search.cgi accession no. 0706 *
TAIHEI YAMANE ET AL.: "Highly regioselective direct halogenation: a simple and efficient method for preparing 4-halomethyl-5-methyl-2-aryl-1,3-thiazoles", TETRAHEDRON LETTERS, vol. 45, 2004, pages 69 - 73 *

Also Published As

Publication number Publication date
JP6218798B2 (ja) 2017-10-25
JP2014509317A (ja) 2014-04-17
KR20120091651A (ko) 2012-08-20
US10045923B2 (en) 2018-08-14
KR101395146B1 (ko) 2014-05-16
US20140037564A1 (en) 2014-02-06
US8889881B2 (en) 2014-11-18
US20150366776A1 (en) 2015-12-24
WO2012108689A2 (ko) 2012-08-16
US9155690B2 (en) 2015-10-13
US20150017111A1 (en) 2015-01-15
JP5856186B2 (ja) 2016-02-09
JP2016121130A (ja) 2016-07-07

Similar Documents

Publication Publication Date Title
WO2012108689A3 (ko) 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도
WO2012108677A3 (ko) 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도
BR112013015855A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
BR112013015859A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica
HK1210082A1 (zh) 西番莲种子提取物及含有其的化妆品、药物、皮肤病学和营养学组合物
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
NZ727304A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
UA111148C2 (uk) Сигма-ліганди для застосування при профілактиці і/або лікуванні післяопераційного болю
NZ701607A (en) Therapeutic use of chardonnay seed products
WO2011129765A9 (en) Synergistic interaction of at least one vitamin e component and tyrosinase inhibitors for dermatological applications
WO2011039735A3 (en) Compounds with ddx3 inhibitory activity and uses thereof
WO2013174774A3 (en) Cosmetic compositions comprising magnetosomes and uses thereof
WO2012076109A3 (de) 2-pyrone
WO2011121250A3 (fr) Composition cosmetique et pharmaceutique comprenant de la n-acetyl-glucosamine- 6 - phosphate
UA107687C2 (ru) Комбинированная композиция, которая в качестве активных ингредиентов содержит l-карнитин или пропионил-l-карнитин, троксерутин, диосмин и гесперидин, для предотвращения и/или лечения хронических заболеваний вен.
WO2013059233A3 (en) Thermoresponsive compositions for dermatological use and methods thereof
MY161419A (en) Skin collagen production-promoting agent
WO2013025073A3 (ko) 유홍초 추출물을 함유하는 당뇨합병증 예방 또는 치료용 조성물
MX353580B (es) Acido graso monoinsaturado para prevenir y/o tratar las imperfecciones del color de la piel.
WO2012108676A3 (ko) 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도
WO2013000895A9 (en) Dha and epa in the reduction of oxidative stress
WO2011118957A3 (ko) 파프리카 추출물을 함유하는 염증, 알레르기 또는 천식 질환 치료용 조성물
PL2731584T3 (pl) Zastosowanie związków oligosacharydowych do zapobiegania i leczenia patologicznych blizn
WO2010051138A3 (en) Skin treatments containing carboxylic acid-substituted idebenone derivatives and methods of preparation and use thereof
WO2014022807A3 (en) Compositions and methods of using the compositions for plaque softening

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12745106

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013553357

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13984567

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 12745106

Country of ref document: EP

Kind code of ref document: A2